JP7691927B2 - Ｔ細胞調節抗原提示ポリペプチド及びその使用方法 - Google Patents

Ｔ細胞調節抗原提示ポリペプチド及びその使用方法 Download PDF

Info

Publication number
JP7691927B2
JP7691927B2 JP2021543384A JP2021543384A JP7691927B2 JP 7691927 B2 JP7691927 B2 JP 7691927B2 JP 2021543384 A JP2021543384 A JP 2021543384A JP 2021543384 A JP2021543384 A JP 2021543384A JP 7691927 B2 JP7691927 B2 JP 7691927B2
Authority
JP
Japan
Prior art keywords
polypeptide
amino acid
cases
acid sequence
mhc class
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021543384A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022522404A (ja
JPWO2020180501A5 (enExample
Inventor
ザ サード ロナルド ディー． セイデル
ロドルフォ ジェイ． チャパーロ
Original Assignee
キュー バイオファーマ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by キュー バイオファーマ， インコーポレイテッド filed Critical キュー バイオファーマ， インコーポレイテッド
Publication of JP2022522404A publication Critical patent/JP2022522404A/ja
Publication of JPWO2020180501A5 publication Critical patent/JPWO2020180501A5/ja
Application granted granted Critical
Publication of JP7691927B2 publication Critical patent/JP7691927B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70532—B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/605—MHC molecules or ligands thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6056—Antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Rehabilitation Therapy (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
JP2021543384A 2019-03-06 2020-02-21 Ｔ細胞調節抗原提示ポリペプチド及びその使用方法 Active JP7691927B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962814715P 2019-03-06 2019-03-06
US62/814,715 2019-03-06
PCT/US2020/019244 WO2020180501A1 (en) 2019-03-06 2020-02-21 T-cell modulatory antigen-presenting polypeptides and methods of use thereof

Publications (3)

Publication Number Publication Date
JP2022522404A JP2022522404A (ja) 2022-04-19
JPWO2020180501A5 JPWO2020180501A5 (enExample) 2023-03-01
JP7691927B2 true JP7691927B2 (ja) 2025-06-12

Family

ID=72338064

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021543384A Active JP7691927B2 (ja) 2019-03-06 2020-02-21 Ｔ細胞調節抗原提示ポリペプチド及びその使用方法

Country Status (4)

Country Link
US (1) US20220106378A1 (enExample)
EP (1) EP3935079A4 (enExample)
JP (1) JP7691927B2 (enExample)
WO (1) WO2020180501A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL303806B2 (en) 2016-12-22 2024-05-01 Cue Biopharma Inc Multimeric polypeptides modulate T cells and methods for their use
WO2018170168A1 (en) 2017-03-15 2018-09-20 Cue Biopharma, Inc. Methods for modulating an immune response
JP7457302B2 (ja) 2017-04-28 2024-03-28 ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・コロラド・ア・ボディ・コーポレイト Ｈｌａ遺伝子のｒｎａガイドゲノム編集を使用して関節リウマチを処置する方法
KR20200064085A (ko) 2017-09-07 2020-06-05 큐 바이오파마, 인크. 접합 부위를 갖는 t-세포 조절 다량체 폴리펩타이드 및 이의 사용 방법
IL296209A (en) 2020-05-12 2022-11-01 Cue Biopharma Inc Multimeric t-cell modulatory polypeptides and methods of using them
AU2022263441A1 (en) * 2021-04-21 2023-11-09 Cue Biopharma, Inc. Antigen presenting polypeptide complexes bearing tgf-beta and methods of use thereof
CA3212762A1 (en) * 2021-04-21 2022-10-27 Ronald D. Seidel Iii Mhc class ii t-cell modulatory polypeptides for treating type 1 diabetes mellitus (t1d) and methods of use thereof
EP4337687A1 (en) 2021-05-10 2024-03-20 The Regents of the University of Colorado, a body corporate Engineered hla alleles for treating autoimmunity
US20240270815A1 (en) * 2021-05-26 2024-08-15 Cue Biopharma, Inc. Antigen Presenting Polypeptide Complexes and Methods of Use Thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040234531A1 (en) 2001-05-07 2004-11-25 Sofia Casares Chimeric human leukocyte antigen and epitope-bearing molecules having immunosuppressant activity
JP2013538555A (ja) 2010-07-15 2013-10-17 テクニオン リサーチ アンド ディベロップメント ファウンデーション リミテッド Ｍｈｃクラスｉｉとグルタミン酸デカルボキシラーゼ（ｇａｄ）自己抗原性ペプチドとの天然型複合体に対するｔ細胞受容体様特異性を有する単離された高親和性実体
JP2017519491A (ja) 2014-06-18 2017-07-20 アルバート アインシュタイン カレッジ オブ メディシン，インコーポレイティド ｓｙｎＴａｃポリペプチド及びその使用
WO2017201131A1 (en) 2016-05-18 2017-11-23 Albert Einstein College Of Medicine, Inc. Variant pd-l1 polypeptides, t-cell modulatory multimeric polypeptides, and methods of use thereof
JP2018524267A (ja) 2015-05-06 2018-08-30 ユーティーアイ リミテッド パートナーシップ 持続療法用のナノ粒子組成物

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
DK0648271T3 (da) 1991-08-20 2003-07-21 Us Gov Health & Human Serv Adenovirusmedieret overførsel af gener til mave-/tarmkanal
US5252479A (en) 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
FR2688514A1 (fr) 1992-03-16 1993-09-17 Centre Nat Rech Scient Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
CA2145641C (en) 1992-12-03 2008-05-27 Richard J. Gregory Pseudo-adenovirus vectors
JP3532566B2 (ja) 1993-06-24 2004-05-31 エル． グラハム，フランク 遺伝子治療のためのアデノウイルスベクター
CN1263864C (zh) 1993-10-25 2006-07-12 坎吉公司 重组腺病毒载体及其使用方法
DK0776339T4 (da) * 1994-07-29 2010-05-25 Sunol Molecular Corp MHC-komplekser og anvendelser deraf
US7078387B1 (en) 1998-12-28 2006-07-18 Arch Development Corp. Efficient and stable in vivo gene transfer to cardiomyocytes using recombinant adeno-associated virus vectors
US6287860B1 (en) 2000-01-20 2001-09-11 Isis Pharmaceuticals, Inc. Antisense inhibition of MEKK2 expression
CA2454358A1 (en) 2001-07-19 2003-07-31 Perlan Therapeutics, Inc. Multimeric proteins and methods of making and using same
US10105437B2 (en) 2004-04-28 2018-10-23 Btg International Limited Epitopes related to coeliac disease
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
SI2402754T2 (sl) 2006-03-06 2023-09-29 Amunix Operating Inc. Nestrukturirani rekombinantni polimeri in njihove uporabe
WO2009023270A2 (en) 2007-08-15 2009-02-19 Amunix, Inc. Compositions and methods for modifying properties of biologically active polypeptides
EP3178835B1 (en) 2009-02-03 2019-04-10 Amunix Pharmaceuticals, Inc. Extended recombinant polypeptides and compositions comprising same
US10816554B2 (en) * 2014-04-04 2020-10-27 The Board Of Trustees Of The Leland Stanford Junior University Ligand discovery for T cell receptors
EP3134730A4 (en) 2014-04-24 2018-01-17 Immusant Inc. Methods for diagnosing celiac disease using circulating cytokines/chemokines
BR112017006178A2 (pt) * 2014-11-06 2018-05-02 F. Hoffmann-La Roche Ag região fc, anticorpos, formulação farmacêutica e usos dos anticorpos
JP7372036B2 (ja) * 2016-03-03 2023-10-31 キュー バイオファーマ， インコーポレイテッド Ｔ細胞調節多量体ポリペプチド及びその使用方法
AU2017357865B2 (en) * 2016-11-09 2024-10-31 Uti Limited Partnership Recombinant pMHC class II molecules
KR20200064083A (ko) * 2017-09-07 2020-06-05 큐 바이오파마, 인크. 항원-제시 폴리펩티드 및 이의 사용 방법
JP2023541366A (ja) * 2020-09-09 2023-10-02 キュー バイオファーマ， インコーポレイテッド １型真性糖尿病（ｔ１ｄ）を治療するためのｍｈｃクラスｉｉ ｔ細胞調節多量体ポリペプチド及びその使用方法

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040234531A1 (en) 2001-05-07 2004-11-25 Sofia Casares Chimeric human leukocyte antigen and epitope-bearing molecules having immunosuppressant activity
JP2013538555A (ja) 2010-07-15 2013-10-17 テクニオン リサーチ アンド ディベロップメント ファウンデーション リミテッド Ｍｈｃクラスｉｉとグルタミン酸デカルボキシラーゼ（ｇａｄ）自己抗原性ペプチドとの天然型複合体に対するｔ細胞受容体様特異性を有する単離された高親和性実体
JP2017519491A (ja) 2014-06-18 2017-07-20 アルバート アインシュタイン カレッジ オブ メディシン，インコーポレイティド ｓｙｎＴａｃポリペプチド及びその使用
JP2018524267A (ja) 2015-05-06 2018-08-30 ユーティーアイ リミテッド パートナーシップ 持続療法用のナノ粒子組成物
WO2017201131A1 (en) 2016-05-18 2017-11-23 Albert Einstein College Of Medicine, Inc. Variant pd-l1 polypeptides, t-cell modulatory multimeric polypeptides, and methods of use thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Eur. J. Immunol. ，2005年，Vol.35, No.9，pp.2762-2775 ，doi: 10.1002/eji.200526158
Mol. Immunol. ，2015年，Vol.63, No.2，pp.456-463 ，doi: 10.1016/j.molimm.2014.09.017.
Physiol Res.，2007年，Vol.56, No.3，pp.255-266，doi: 10.33549/physiolres.930956

Also Published As

Publication number Publication date
US20220106378A1 (en) 2022-04-07
JP2022522404A (ja) 2022-04-19
EP3935079A4 (en) 2023-03-22
WO2020180501A1 (en) 2020-09-10
EP3935079A1 (en) 2022-01-12

Similar Documents

Publication Publication Date Title
JP7691927B2 (ja) Ｔ細胞調節抗原提示ポリペプチド及びその使用方法
US20240034767A1 (en) Antigen-presenting polypeptides and methods of use thereof
JP7560641B2 (ja) 融合ポリペプチド、医薬組成物、核酸、宿主細胞、及び融合ポリペプチドを作成する方法
JP7331075B2 (ja) ｓｙｎＴａｃポリペプチド及びその使用
AU2018328280B2 (en) Multimeric T-cell modulatory polypeptides and methods of use thereof
AU2019404285B2 (en) Multimeric T-cell modulatory polypeptides and methods of use thereof
JP7481342B2 (ja) 多量体ｔ細胞調節ポリペプチド及びその使用方法
US20220135645A1 (en) Antigen-Presenting Polypeptides with Chemical Conjugation Sites and Methods of Use Thereof
US20220079985A1 (en) T-Cell Modulatory Multimeric Polypeptides with Conjugation Sites and Methods of Use Thereof
US20240082411A1 (en) T-Cell Modulatory Polypeptides with Conjugation Sites and Methods of Use Thereof
US20220008467A1 (en) T-Cell Modulatory Multimeric Polypeptides with Conjugation Sites and Methods of Use Thereof
US20240376177A1 (en) Multimeric t-cell modulatory polypeptides and methods of use thereof
US20240368245A1 (en) Multimeric t-cell modulatory polypeptides and methods of use thereof
US12029782B2 (en) MHC class II T-cell modulatory multimeric polypeptides for treating type 1 diabetes mellitus (T1D) and methods of use thereof
US20230241192A1 (en) Multimeric t-cell modulatory polypeptides and methods of use thereof
HK40060108A (en) Multimeric t-cell modulatory polypeptides and methods of use thereof
EA047549B1 (ru) Модулирующие т-клетки мультимерные полипептиды и способы их применения

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230220

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230220

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20230530

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240117

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240229

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240524

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240902

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250106

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250108

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20250108

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250515

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250602

R150 Certificate of patent or registration of utility model

Ref document number: 7691927

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150